This website uses its own and third party technical cookies, solely to ensure enhanced navigation and to gather anonymous statistical navigation data without any user profiling.

If you wish to learn more or deny consent to all or some cookies click here.

If you access any element below this banner you automatically consent to the use of cookies.



Drug attrition rate in clinical trials is almost 90% and is primarily due to the high incidence of adverse effects. We offer an early-stage toxicity assessment tool that integrates with small, non-GLP, preclinical conventional toxicology and improves predictivity of such studies in combination with well established toxicological parameters.

Toxicogenomics has the potential to be used as a key decision tool in drug discovery and development. Toxicogenomics is the study of drug related safety/toxicity at the gene expression level and helps to:

  • understand mechanisms of toxicity
  • suggest off-target activities of the drug
  • predict toxic effects in an early stage of development
  • discover predictive markers of toxicity